Everything below concerns Freeze-thaw. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
== Evolutionary view == Multiple urocortin genes are present in vertebrate lineages as a result of the two waves of vertebrate whole-genome duplication. Two ligands, the CRF/UCN1 and UCN2/UCN3 paralogs, and two receptors, CRFR1 and CRFR2, were produced by a first genome duplication in early vertebrates. The CRF system observed in modern vertebrates, which has four ligands and two receptors, was then created by a second genome duplication that split the gene between UCN2 and UCN3 and between CRF and UCN1. Two peptide genes were hypothesized to have been present in a vertebrate progenitor that gave rise to the different lineages that contained urocortin (UCN I), CRH1, and CRH2 in one group and urocortin II (UCN II) and urocortin III (UCN III ) in the other. In many vertebrates, there are five members of the corticotropin-releasing hormone and urocortin family of peptides: CRH (crha/crhb in teleosts), CRH2, UCN/UTS1, UCN II, and UCN III. The two receptors, CRFR1 and CRFR2, and the four ligands, CRF, Urocortin1 (UCN1), UCN2, and UCN3, make up the mammalian CRF system. Genes for mentioned proteins can perform a multitude of tasks in a wide range of animals due to differences in their expression patterns and receptor affinities.
Lipases are a type of enzyme that break down fats. More specifically, lipases use water (as hydrolases) to remove fatty acids from fat molecules, especially triglycerides or its derivatives. In humans and other animals, lipases have a variety of roles in the body, from helping digest dietary fats like pancreatic lipase, to synthesizing fat-based hormones like diglyceride lipases. What counts as a lipase is not consistently defined across sources, and some only consider enzymes to be lipases if they are activated by oil-water interfaces. Many specific lipases can also catalyze other reactions. For example, carboxyl ester lipase is able to remove fatty acids that are attached to cholesterol, while endothelial lipase can remove fatty acids from phospholipids (a major component of cell membranes).
The activation of the endogenous opioids is for an analgesic effect using the gate control theory of pain. In addition, deep dry may also decrease pain, increase range of motion, and minimize myofascial trigger point irritability. In regards to the factor of pain reduction, relief occurs at four central levels: local pain, spinal pain through nerves, brain stem pain, and higher brain center pain. The relief of myofascial trigger points has been more highly researched than the relief of connective tissues, muscle fascia, muscle tension, and scar tissue; however, the American Physical Therapy Association claims that there potentially may be some benefits of dry needling on these ailments according to some available evidence. The APTA also claims that dry needling should not be used as a standalone procedure, but should be used in conjunction with other treatment methods, including manual soft tissue mobilization, neuromuscular re-education, functional retraining, and therapeutic exercises. Once the needle is inserted, one can manually or electrically stimulate the filiform needle depending for the desired effect of treatment.
=== Hormonal === Hormones are signaling molecules used to regulate bodily behavior and are believed to play a role in cachexia as well. Glucocorticoids are produced as part of the body's natural response to stress. They are also known to play a role in muscle breakdown. Furthermore, people with long-term illness such as cancer are frequently treated with glucocorticoids, making cachexia more likely in these individuals. Some tumors produce a molecule called parathyroid-related peptide (PTHrP). It increases metabolism by stimulating energy production in the mitochondria of fat cells. Leptin is a hormone known to decrease appetite. People with cachexia often have high leptin levels, making them feel less hungry. The hypothalamus, the brain's appetite control center, is also affected in cachexia. Given the hypothalamic function in controlling appetite, it is believed to play a role in cachexia. The appetite-controlling center of the hypothalamus is controlled by neuropeptide Y (NPY) and agouti gene-related protein (AgRP) that increase appetite, as well as proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) that decrease appetite. Inflammation may disrupt these appetite signals, causing reduced hunger and leading to further weight and muscle loss. However, scientists are still studying exactly how this process works.
Sources: en.wikipedia.org
===== Linear or reticular opacities ===== Acute: Pulmonary edema Chronic: Idiopathic pulmonary fibrosis Connective tissue-associated interstitial lung diseases Asbestosis Sarcoidosis Hypersensitivity pneumonitis Drug-induced lung disease
=== Sense of self and self-concept === Individuals diagnosed with BPD frequently experience significant difficulties in maintaining a stable self-concept. This identity disturbance manifests as uncertainty in personal values, beliefs, preferences, and interests. They may also express confusion regarding their aspirations and objectives in terms of relationships and career paths. Such indeterminacy leads to feelings of emptiness and a profound sense of disorientation regarding their own identity. Moreover, their self-perception can fluctuate dramatically over short periods, oscillating between positive and negative evaluations. Consequently, individuals with BPD might adopt their sense of self based on their surroundings or the people they interact with, resulting in a chameleon-like adaptation of identity, known as mirroring. This can also often lead to pervasive emotional contagion.
The 4th Panzer Army (German: 4. Panzerarmee), operating as Panzer Group 4 (Panzergruppe 4) from its formation on 15 February 1941 to 1 January 1942, was a German panzer formation during World War II. As a key armoured component of the Wehrmacht, the army took part in the crucial battles of the German-Soviet war of 1941–45, including Operation Barbarossa, the Battle of Moscow, the Battle of Stalingrad, the Battle of Kursk, and the 1943 Battle of Kiev. The army was destroyed during the Battle of Stalingrad, but later reconstituted.
Applications in the musculoskeletal system include spinal imaging, assessment of joint disease, and soft tissue tumors. MRI techniques can also be used for diagnostic imaging of systemic muscle diseases including genetic muscle diseases. Swallowing movements of the throat and esophagus can cause motion artifacts over the imaged spine. Therefore, a saturation pulse applied over this region can help to avoid these artifacts. Motion artifacts arising due to the pumping of the heart can be reduced by timing the MRI pulse according to heart cycles. Blood vessel flow artifacts can be reduced by applying saturation pulses above and below the region of interest.
The road currently visible presents the last state of its construction in the Later Roman Empire around the 4th century. It was made using large slabs of Cassis stone, very resistant to the traffic of heavy carts. The wide grooves are still visible. They were made to prevent the wheels from slipping, while the holes visible in the middle of the slabs were intended for handling and positioning them. On the edges of the roadway, there is a sidewalk.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.